Abstract:
Objective To analyze the efficacy of multiple treatments including hydroxychloroquine used in early time on the chest imaging changes of coronavirus disease 2019(COVID-19) patients.
Methods Clinical data including general information, clinical performance, lab indexes, imaging performance, treatment schemes, and prognosis were retrospectively collected.Binary logistic regression was used to screen the factors associated with advances in chest imaging, and Cox proportional hazards model was used to estimate the effects of prognostic factors on the improvement time in chest imaging.Kaplan-Meier curves were used to analyze the effect of hydroxychloroquine used early on imaging prognosis of patients.
Results A total of 498 non-light patients were selected, including 48(86.35%) common patients, 50(10.04%) severe patients, and 18(3.61%) critical patients, with a median age of 43(32, 59) years.Among them, 176(35.34%) patients were treated with hydroxychloroquine.The early use of hydroxychloroquine was a favorable factor for the imaging improvement (95% CI 0.517-0.870, P=0.003).The median time to imaging improvement was 7 d in the hydroxychloroquine used early group, which was 9 d in the without hydroxychloroquine used group (P < 0.001).
Conclusions Early use of hydroxychloroquine could improve chest imaging changes of patients with COVID-19.